GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » 3-Year FCF Growth Rate

BioRestorative Therapies (FRA:9OF) 3-Year FCF Growth Rate : 17.10% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies 3-Year FCF Growth Rate?

BioRestorative Therapies's Free Cash Flow per Share for the three months ended in Dec. 2023 was €-0.36.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 17.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 76.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 66.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of BioRestorative Therapies was 88.80% per year. The lowest was -162.80% per year. And the median was 48.50% per year.


Competitive Comparison of BioRestorative Therapies's 3-Year FCF Growth Rate

For the Biotechnology subindustry, BioRestorative Therapies's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's 3-Year FCF Growth Rate falls into.



BioRestorative Therapies 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


BioRestorative Therapies  (FRA:9OF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


BioRestorative Therapies 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRestorative Therapies (FRA:9OF) Business Description

Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies (FRA:9OF) Headlines

No Headlines